LVGN6051

Clinical trials

Phase II

A Study of LVGN6051 Combination Therapy in Patient With Head and Neck Squamous Cell Carcinoma (HNSCC)

NCT06378177

VIEW TRIAL

Phase Ib/II

An Open Label, Phase Ib/II Trial of LVGN6051 Combined With Anlotinib in the Treatment of Locally Advanced, Metastatic or Recurrent Refractory Soft Tissue Sarcoma

NCT05301764

VIEW TRIAL

Phase I

An Open Label, First in Human (FIH), Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Pembrolizumab (MK-3475-A31/KEYNOTE-A31) in Advanced or Metastatic Malignancy

NCT04130542

VIEW TRIAL

An Open Label, Phase 1 Trial of LVGN6051 as Single Agent and in Combination With Pembrolizumab in Advanced or Metastatic Malignancy

NCT04694781

VIEW TRIAL

Study of LVGN3616 and LVGN6051±LVGN7409 in Combination With Nab-Paclitaxel or Bevacizumab and Cyclophosphamide in Metastatic Solid Tumors

NCT05075993

VIEW TRIAL

More about LVGN6051

CD137 is a member of the tumor necrosis factor (TNF) receptor family. Its alternative names are tumor necrosis factor receptor superfamily member 9 (TNFRSF9), 4-1BB and induced by lymphocyte activation (ILA). It is of interest to immunologists as a co-stimulatory immune checkpoint molecule.
CD137 can be expressed by activated T cells, but to a larger extent on CD8 than on CD4 T cells.
The best characterized activity of CD137 is its costimulatory activity for activated T cells. Crosslinking of CD137 enhances T cell proliferation, IL-2 secretion, survival and cytolytic activity. Further, it can enhance immune activity to eliminate tumors in mice.
Upon administration, anti-CD137 agonistic antibody LVGN6051 binds to and activates CD137 expressed on a variety of leukocyte subsets including activated T lymphocytes and natural killer (NK) cells. This enhances CD137-mediated signaling, induces cytokine production and promotes T-cell mediated anti-tumor immune responses.
For more scientific rationale, please visit Cancer Immunotherapy and xLink MAb.

Our Progress

Preliminary antitumor activity in late stage cancer patients was observed Phase I trials of LVGN6051 alone or in combination with anti-PD-1 antibody in the USA, in combination with VEGFR TKI anlotinib in China, in adult patients with advanced malignancies. Combination with pembrolizumab induced rapid antitumor responses in advanced cancer patients with immune-cold tumor or relapsed from prior immunotherapies. The relative clinical results are selected for ASCO 2024.

We are currently preparing the Phase II study of LVGN6051 combination therapy in patient with head and neck squamous cell carcinoma (HNSCC).

If you as a patient or caregiver wish to participate in this study, please send us a message